The Correlation of a Sarcoidosis Clinical Outcome Score to Patient Demographics and Sarcoidosis Organ Involvement

Author(s):  
K. Hu ◽  
R. Reeves ◽  
J.M. Zeigler ◽  
M.A. Judson ◽  
D.A. Culver ◽  
...  
2015 ◽  
Vol 99 (6) ◽  
pp. 2124-2132 ◽  
Author(s):  
Andrew S. Mackie ◽  
Shabnam Vatanpour ◽  
Gwen Y. Alton ◽  
Irina A. Dinu ◽  
Lindsay Ryerson ◽  
...  

2006 ◽  
Vol 7 (Supplement) ◽  
pp. S26
Author(s):  
Vamsi Yarlagadda ◽  
David Wypij ◽  
Peter Laussen ◽  
Stephen Roth ◽  
Andrew Mackie ◽  
...  

2013 ◽  
Vol 145 (5) ◽  
pp. 1248-1254.e2 ◽  
Author(s):  
Andrew S. Mackie ◽  
Gwen Y. Alton ◽  
Irina A. Dinu ◽  
Ari R. Joffe ◽  
Stephen J. Roth ◽  
...  

2011 ◽  
Vol 27 (5) ◽  
pp. S210-S211
Author(s):  
A.S. Mackie ◽  
G.Y. Alton ◽  
I. Dinu ◽  
A.R. Joffe ◽  
S.J. Roth ◽  
...  

2014 ◽  
Vol 30 (10) ◽  
pp. S173-S174
Author(s):  
A.S. Mackie ◽  
S. Vatanpour ◽  
G.Y. Alton ◽  
I.A. Dinu ◽  
L. Ryerson ◽  
...  

2016 ◽  
Vol 9 (6) ◽  
pp. 535-540 ◽  
Author(s):  
Ruchi Kabra ◽  
Timothy J Phillips ◽  
Jacqui-Lyn Saw ◽  
Constantine C Phatouros ◽  
Tejinder P Singh ◽  
...  

ObjectiveTo audit our institutional mechanical thrombectomy (MT) outcomes for acute anterior circulation stroke and examine the influence of workflow time metrics on patient outcomes.MethodsA database of 100 MT cases was maintained throughout May 2010—February 2015 as part of a statewide service provided across two tertiary hospitals (H1 and H2). Patient demographics, stroke and procedural details, blinded angiographic outcomes, and 90-day modified Rankin Scale (mRS) scores were recorded. The following time points in stroke treatment were recorded: stroke onset, hospital presentation, CT imaging, arteriotomy, and recanalization. Statistical analysis of outcomes, predictors of outcome, and differences between the hospitals was carried out.ResultsThrombolysis in Cerebral Infarction (TICI) 2b/3 reperfusion was 79%. Forty-nine per cent of patients had good clinical outcomes (mRS 0–2). In a subgroup analysis of 76 patients with premorbid mRS 0–1 and first CT performed ≤4.5 h after stroke onset, 60% had good clinical outcomes. Patient and disease characteristics were matched between the two hospitals. H1 had shorter times between hospital presentation and CT (32 vs 55 min, p=0.01), CT and arteriotomy (33 vs 69 min, p=0.00), and stroke onset and recanalization (198 vs 260 min, p=0.00). These time metrics independently predicted good clinical outcome. Median days spent at home in the first 90 days was greater at H1 (61 vs 8, p=0.04) than at H2. A greater proportion of patients treated at H1 were independent (mRS 0–2) at 90 days (54% vs 42%); however, this was not statistically significant (p=0.22).ConclusionsOutcomes similar to randomized controlled trials are attainable in ‘real-world’ settings. Workflow time metrics were independent predictors of clinical outcome, and differed between the two hospitals owing to site-specific organizational differences.


2019 ◽  
pp. jramc-2018-001117 ◽  
Author(s):  
A B Bayoumy ◽  
E L van der Veen ◽  
P-J A M van Ooij ◽  
F S Besseling-Hansen ◽  
D A A Koch ◽  
...  

IntroductionAcute acoustic trauma (AAT) is a sensorineural hearing impairment due to exposure to an intense impulse noise which causes cochlear hypoxia. Hyperbaric oxygen therapy (HBO) could provide an adequate oxygen supply. The aim was to investigate the effectiveness of early treatment with combined HBO and corticosteroid therapy in patients with AAT compared with corticosteroid monotherapy.MethodsA retrospective study was performed on military personnel diagnosed with AAT between November 2012 and December 2017. Inclusion criteria for HBO therapy were hearing loss of 30 dB or greater on at least one, 25 dB or more on at least two, or 20 dB or more on three or more frequencies as compared with the contralateral ear.ResultsAbsolute hearing improvements showed significant differences (independent t-test) between patients receiving HBO and the control group at 500 Hz (p=0.014), 3000 Hz (p=0.023), 4000 Hz (p=0.001) and 6000 Hz (p=0.01) and at the mean of all frequencies (p=0.002). Relative hearing improvements were significantly different (independent t-test) at 4000 Hz (p=0.046) and 6000 Hz (p=0.013) and at all frequencies combined (p=0.005). Furthermore, the percentage of patients with recovery to the functional level required by the Dutch Armed Forces (clinical outcome score) was higher in the HBO group.ConclusionsEarly-stage combination therapy for patients with AAT was associated with better audiometric results at higher frequencies and better clinical outcome score.


2003 ◽  
Vol 64 (3) ◽  
pp. 316-320 ◽  
Author(s):  
Hsien-Yuan Lane ◽  
Yue-Cune Chang ◽  
Yiao-Cheung Cheng ◽  
Guang-Chyi Liu ◽  
Xing-Ru Lin ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
S. C. Sasson ◽  
L. E. Wilkins ◽  
R. A. Watson ◽  
C. Jolly ◽  
O. Brain ◽  
...  

AbstractDevelopment of anti-drug antibodies (ADAs) can interfere with therapeutic monoclonal antibodies and may lead to drug neutralisation and clinical disease progression. Measurement of circulating drug levels and development of ADAs in the setting of anti-programmed cell death-1 agent pembrolizumab has not been well-studied. Enzyme-linked immunosorbent assays were used to measure pembrolizumab drug level and ADAs in 41 patients with melanoma at baseline, Time-point 1 (3 weeks) and Time-point 2 (21 weeks). Assay results were related to patient demographics and clinical outcome data at 6 months. The median pembrolizumab drug level at 3 weeks was 237 ng/μL and did not correlate with age, sex or body surface area.17/41 patients had an ADA detected at any timepoint, with the highest prevalence at Timepoint 1 (median concentration = 17 ng/μL). The presence of an ADA did not correlate with clinical progression at 6 months. 3/41 (7%) of patients displayed a falling pembrolizumab drug level and rising ADA titre between Timepoint 1 and 2 suggestive of a neutralising ADA. Pembrolizumab drug levels and ADAs can be readily measured. The rates of total and treatment-emergent ADAs may be higher in “real-word” settings than those previously reported. Larger studies are needed to determine effect of neutralising ADAs on long-term clinical outcome.


2020 ◽  
Vol 41 (9) ◽  
pp. 1065-1072
Author(s):  
Omar A. Behery ◽  
Jessica Mandel ◽  
Sara J. Solasz ◽  
Sanjit R. Konda ◽  
Kenneth A. Egol

Background: The purpose of this study was to identify characteristic patterns of syndesmotic screw (SS) failure, and any effects on clinical outcome. Methods: A retrospective study was performed using a consecutive series of patients treated with open reduction and internal fixation with trans-syndesmotic screws for unstable ankle fractures with syndesmotic injury between 2015 and 2017. Patient demographics, fracture characteristics and classification, rates and patterns of trans-syndesmotic screw breakage, and backout were analyzed. Functional outcome was assessed using passive range of motion (ROM) and Maryland Foot Score (MFS). Results: A total of 113 patients (67%) had intact screws and 56 patients (33%) demonstrated either screw breakage or backout. Patients with SS failure were younger ( P = .002) and predominantly male ( P = .045). Fracture classification and energy level of injury were not associated with screw failure. Nine screws (11%) demonstrated backout (2 also broke) and 56 other screws broke. There was no association between the number of screws or cortices of purchase and screw failure. There was a trend toward a higher proportion of screw removal (20%) in this failed SS group compared with the intact SS group (12%) ( P = .25), but with similar ankle ROM and MFS ( P > .07). Conclusion: Syndesmotic screw breakage was common in younger, male patients. Despite similarities in ankle range of motion and clinical outcome scores to patients with intact screws, there was a trend towards more frequent screw removal. This information can be used to counsel patients pre- and postoperatively regarding the potential for screw failure and subsequent implant removal. Level of Evidence: Level III, retrospective case-control study.


Sign in / Sign up

Export Citation Format

Share Document